Current Use and Promise of Urinary Markers for Urothelial Cancer.

Autor: Tabayoyong W; The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd. Unit 1373, Houston, TX, 77030, USA., Kamat AM; The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd. Unit 1373, Houston, TX, 77030, USA. akamat@mdanderson.org.
Jazyk: angličtina
Zdroj: Current urology reports [Curr Urol Rep] 2018 Oct 17; Vol. 19 (12), pp. 96. Date of Electronic Publication: 2018 Oct 17.
DOI: 10.1007/s11934-018-0857-1
Abstrakt: Purpose of Review: We summarize the current literature regarding the available urinary biomarkers for the detection and surveillance of bladder cancer.
Recent Findings: Four urinary biomarkers have FDA approval for the detection of bladder cancer; however, they have not supplanted cystoscopy and urine cytology as the gold standard. Recent technological advances in next-generation sequencing have allowed the field of urinary biomarker research to move beyond protein biomarkers and now include genomic, transcriptomic, and epigenetic panels. The search for a noninvasive, inexpensive urinary biomarker for the detection of bladder cancer that can replace cystoscopy and cytology continues. There are several promising genomic, transcriptomic, and epigenetic marker panels in development; however, these new tests require further prospective validation before widespread clinical implementation.
Databáze: MEDLINE
Externí odkaz: